US EditionAlnylam wins FDA approval for rare heart disease drug
- The Food and Drug Administration approved Alnylam Pharmaceuticals' drug Amvuttra for transthyretin amyloidosis with cardiomyopathy, a serious heart condition, on Thursday.
- Amvuttra led to a 28% lower risk of cardiovascular events or death in clinical testing compared to a placebo.
- Alnylam's CEO Yvonne Greenstreet stated that Amvuttra offers a clinically differentiated treatment option that has been shown to improve outcomes.
- The company expects Amvuttra and Onpattro to generate $1.6 billion to $1.7 billion combined this year, up from just over $1.2 billion last year.
19 Articles
19 Articles
FDA Expands Approval for Alnylam’s Drug to Treat Rare Heart Disease
The Food and Drug Administration approved Alnylam’s drug to treat a rare and deadly heart disease on Thursday, allowing the entry of a new type of medicine in a market dominated by Pfizer’s blockbuster Vyndaqel. Alnylam is banking on the success of the drug, chemically called vutrisiran, to reach profitability and invest in future treatments. Its drug will compete in the market for transthyretin amyloid cardiomyopathy (ATTR-CM) treatments, which…
Vutrisiran Snags FDA Approval for TTR Amyloidosis Cardiomyopathy
(MedPage Today) -- Gene-silencing therapy vutrisiran (Amvuttra) graduated to a broad indication in treatment of transthyretin amyloidosis cardiomyopathy, as Alnylam Pharmaceuticals announced expanded FDA approval. Vutrisiran, a transthyretin-directed...
Coverage Details
Bias Distribution
- 67% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
